Cairo – Mubasher: The extraordinary general assembly (EGM) of Memphis Pharmaceutical and Chemical Industries has approved the continuity of the company’s activity, during a meeting held on Thursday, 13 October 2022.
In the meantime, the company’s general assembly approved the financial statements for the fiscal year (FY) ended on 30 June 2022 as well as the board’s report on the company’s activity and financial position during FY21/22, according to a stock exchange statement on Sunday.
During the period from July 2021 to June 2022, the adjusted financial statements of Memphis Pharmaceutical indicated a 77% annual hike in profits at EGP 74.08 million, compared to EGP 41.80 million a year earlier.
